• News
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Management
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
    • Presentations
    • The Share
      • Largest Shareholders
      • Rights Issue / Företrädesemission 2020
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Contact
logo
  • News
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Management
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
    • Presentations
    • The Share
      • Largest Shareholders
      • Rights Issue / Företrädesemission 2020
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Contact
Home / Investors / Financial Reports – Swedish
  • Overview
  • Press Releases
    • English
    • Swedish
    • Subscribe
  • Presentations
  • The Share
    • Share Monitor
    • Largest Shareholders
    • Rights Issue / Företrädesemission 2020
    • Previous Share Issuances
    • Analyst Coverage
  • Financial Reports
    • English
    • Swedish
  • Financial Calendar
  • Corporate Governance
    • General Meetings
    • Auditor
    • Articles of Association
    • Board of Directors
    • Management
  • Certified Adviser
  • IR Contact

Finansiella Rapporter

Räkenskapsåret for Alzinova AB följer kalenderåret. Finansiella rapporter har upprättats i enlighet med årsredovisningslagen och Bokföringsnämndens allmänna råd, och vidare presenterade enligt Nasdaq First North Growth Markets regelverk.

2020

Alzinova delårsrapport 1 Läs Alzinova delårsrapport 2 Läs Alzinova delårsrapport 3 Läs Alzinova Bokslutskommuniké Läs

2019

Alzinova Årsredovisning Läs Alzinova Bokslutskommuniké Läs Alzinova Q3 Läs Alzinova H1 Läs Alzinova delårsrapport 1 Läs

2018

Alzinova Årsredovisning Läs

2017

Alzinova Årsredovisning Läs

2016

Alzinova Årsredovisning Läs

2015

Alzinova Årsredovisning Läs
  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB. Pepparedsleden 1, SE-431 83, Mölndal, Sweden
+46 (0) 708 467 975   info@alzinova.com

Follow us on

follow us on linkedin